Category: 66855-92-3

Ruzo, Luis O.; Unai, Tadaaki; Casida, John E. published an article in 1978, the title of the article was Decamethrin metabolism in rats.Electric Literature of 66855-92-3 And the article contains the following content:

On oral administration to male rats, the pyrethroid insecticide decamethrin (I) [52918-63-5] and various metabolites derived from its acid and alc. fragments were almost completely eliminated from the body within 2-4 days. Metabolites of the cyano substituent were eliminated more slowly, especially from the skin and stomach, due in the latter case to temporary retention of thiocyanate which was formed from released cyanide. The excreted metabolites included: esters monohydroxylated at the 2′, 4′, and 5 positions of the alc. moiety; 2,2-dimethyl-3-(2,2-dibromovinyl)cyclopropanecarboxylic acid [59952-39-5] and its glucuronide [66855-97-8] and glycine conjugate [66855-98-9] and a hydroxylated derivative [66855-99-0] of this acid, with the hydroxymethyl group trans to the carboxyl, and its glucuronide [66856-00-6]; 3-phenoxybenzoic acid [3739-38-6] and its glucuronide [57991-35-2] and glycine conjugate [57991-36-3], 3-(4-hydroxyphenoxy)benzoic acid [35065-12-4] and its glucuronide [66856-01-7] and sulfate conjugate [58218-91-0], and 3-(2-hydroxyphenoxy)benzoic acid sulfate [61183-26-4]; thiocyanate [302-04-5] and 2-iminothiazolidine-4-carboxylic acid [2150-55-2]. Trans-Decamethrin [64363-96-8] was also rapidly metabolized in rats. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Electric Literature of 66855-92-3

The Article related to decamethrin metabolism rat, Toxicology: Agrochemical and other aspects.Electric Literature of 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On May 4, 2006, Ghosh, Shomir; Elder, Amy; Guo, Jianping; Mani, Ukti; Patane, Michael; Carson, Kenneth; Ye, Qing; Bennett, Robert; Chi, Shannon; Jenkins, Tracy; Guan, Bing; Kolbeck, Roland; Smith, Sean; Zhang, Cheng; LaRosa, Gregory; Jaffee, Bruce; Yang, Hua; Eddy, Priya; Lu, Chuang; Uttamsingh, Vinita; Horlick, Robert; Harriman, Geraldine; Flynn, Daniel published an article.Reference of 3-(2-Methoxyphenoxy)benzaldehyde The title of the article was Design, Synthesis, and Progress toward Optimization of Potent Small Molecule Antagonists of CC Chemokine Receptor 8 (CCR8). And the article contained the following:

Activation of CCR8 by its ligand CCL1 may play an important role in diseases such as asthma, multiple sclerosis, and cancer. The study of small mol. CCR8 antagonists will help establish the validation of these hypotheses. We report the design, synthesis, and progress toward optimization of potent small mol. CCR8 antagonists identified from a high-throughput screen. These analogs exhibit good potency in binding and chemotaxis assays, show good selectivity vs. the hERG channel, and have good eADME (early absorption, distribution, metabolism, and excretion) profiles. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Reference of 3-(2-Methoxyphenoxy)benzaldehyde

The Article related to ccr8 antagonist preparation sar herg channel, Pharmacology: Structure-Activity and other aspects.Reference of 3-(2-Methoxyphenoxy)benzaldehyde

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 15, 2018, Biediger, Ronald J.; Benish, Michele A.; Hardy, Lindsay Bonner; Boyd, Vincent A.; Market, Robert V.; Thrash, Thomas P.; Young, Brandon M. published a patent.HPLC of Formula: 66855-92-3 The title of the patent was Preparation of propionic acid derivatives as α4-integrin inhibitors. And the patent contained the following:

The title compounds I [R1 and R2 = (independently) H, halo, alkyl, cycloalkyl, or arylalkyl; R3 = hydroxy or oxido paired with a pharmaceutically acceptable cation.; R4 = hydroxy, alkoxy, or oxido paired with a pharmaceutically acceptable cation; R5 = (un)substituted Ph, aryl, heteroaryl or arylalkyl; X = CH2, O, or CF2; R6 = (un)substituted alkyl, Ph, aryl, heteroaryl] or pharmaceutically acceptable salts or stereoisomers thereof, useful for antagonizing the action of an α4-integrin to treat various pathophysiol. conditions, were prepared E.g., a multi-step synthesis of sodium 3-[3-(1,5-dimethyl-4-oxido-2-oxo-1,2-dihydropyridin-3-yl)ureido]-3-(3-phenoxyphenyl)propanoate (II), starting from Me propionylacetate and Me formate, was described. Exemplified compounds I were evaluated for their activities as α4-integrin inhibitors (data given for representative compounds I). Pharmaceutical composition comprising compound I was described. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).HPLC of Formula: 66855-92-3

The Article related to propionic acid derivative propanoate pyridinylureido preparation alpha4 integrin inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.HPLC of Formula: 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 1, 2018, Biediger, Ronald J.; Benish, Michele A.; Market, Robert V.; Savage, Michael M.; Young, Brandon M. published a patent.Application of 66855-92-3 The title of the patent was Preparation of propionic acid derivatives as α4-integrin inhibitors. And the patent contained the following:

The title compounds I [R1 and R2 = (independently) H, halo, alkyl, cycloalkyl, or arylalkyl; R3 = hydroxy or oxido paired with a pharmaceutically acceptable cation.; R4 = hydroxy, alkoxy, or oxido paired with a pharmaceutically acceptable cation; R5 = (un)substituted Ph, aryl, heteroaryl or arylalkyl; X = CH2, O, or CF2; R6 = (un)substituted alkyl, Ph, aryl, heteroaryl] or pharmaceutically acceptable salts or stereoisomers thereof, useful for antagonizing the action of an α4-integrin to treat various pathophysiol. conditions, were prepared E.g., a multi-step synthesis of sodium 3-[3-(1,5-dimethyl-4-oxido-2-oxo-1,2-dihydropyridin-3-yl)ureido]-3-(3-phenoxyphenyl)propanoate (II), starting from Me propionylacetate and Me formate, was described. Exemplified compounds I were evaluated for their activities as α4-integrin inhibitors (data given for representative compounds I). Pharmaceutical composition comprising compound I was described. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Application of 66855-92-3

The Article related to propionic acid derivative propanoate pyridinylureido preparation alpha4 integrin inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Application of 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On February 10, 2022, Li, Yong; Liu, Yan; Zhu, Zejiang; Yan, Wei; Zhang, Chufeng; Yang, Zhuang; Bai, Peng; Tang, Minghai; Shi, Mingsong; He, Wen; Fu, Suhong; Liu, Jiang; Han, Kai; Li, Jiewen; Xie, Lixin; Ye, Haoyu; Yang, Jianhong; Chen, Lijuan published an article.Electric Literature of 66855-92-3 The title of the article was Structure-Based Design and Synthesis of N-Substituted 3-Amino-β-Carboline Derivatives as Potent αβTubulin Degradation Agents. And the article contained the following:

Compound I, a noncovalent colchicine-site ligand, was capable of promoting αβ-tubulin degradation was found in previous studies. To further improve its antiproliferative activity, derivatives or analogs II [R1 = n-Pr, n-Bu, cyclopentyl, etc.], III [R3 = Et, 2-FC6H4, 3-pyridyl, etc.] of compound I were designed and synthesized based on 2-tubulin cocrystal structure. Among them, compound III [R3 = 1,3-benzodioxol-5-yl] displayed nanomolar potency against a variety of tumor cells, including paclitaxel- and adriamycin-resistant cell lines. Compound III [R3 = 1,3-benzodioxol-5-yl] binds to the colchicine site and promotes αβ-tubulin degradation in a concentration-dependent manner via the ubiquitin-proteasome pathway. The X-ray crystal structure revealed that compound III [R3 = 1,3-benzodioxol-5-yl] binds in a similar manner as compound I, but there was a slight conformation change of the B ring, which resulted in better interaction of compound III [R3 = 1,3-benzodioxol-5-yl] with surrounding residues. Compound III [R3 = 1,3-benzodioxol-5-yl] effectively suppressed tumor growth at an i.v. dose of 40 mg/kg (3 times a week) on both A2780S (paclitaxel-sensitive) and A2780T (paclitaxel-resistant) ovarian xenograft models, with resp. TGIs of 92.42 and 79.75% without obvious side effects, supporting its potential utility as a tumor-therapeutic compound The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Electric Literature of 66855-92-3

The Article related to amino beta carboline preparation antitumor sar pharmacokinetic human, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Electric Literature of 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On May 8, 2003, Ghosh, Shomir; Patane, Michael A.; Carson, Kenneth G.; Chi, I-Cheng Shannon; Ye, Qing; Elder, Amy M.; Jenkins, Tracy J. published a patent.Synthetic Route of 66855-92-3 The title of the patent was Preparation of compounds as C-C chemokine receptor 8 antagonists, pharmaceutical compositions and use against inflammatory or viral disorders. And the patent contained the following:

The invention relates to (shown as I; variables defined below; e.g. 1-[1-(2′,6′-dichlorobiphenyl-3-ylmethyl)piperidin-4-yl]-1,3-dihydrobenzimidazol-2-one and 3-(3-phenoxybenzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine). Preferred compounds are antagonists of C-C chemokine receptor 8 (no data). The invention also relates to a method for treating a subject having an inflammatory disorder or viral disorder comprising administering to a subject in need thereof an effective amount of a compound of the invention. Although the methods of preparation are not claimed, hundreds of example preparations are included. For I: L = O, S, NRa, a bond, SO2, C(O), and (CR’R”)m; Ra = H, (un)substituted alkyl, alkylaryl, and cycloalkyl; a is 0 to 3; b is 0 to 3; m is 1 to 8; R’ and R” = H, (un)substituted alkyl, cyano and (un)substituted alkenyl. R6, R7, R8, R9 and R10 = H, hydroxy, halogen, (un)substituted C1-C10 alkyl, (un)substituted C2-C10 alkenyl, (un)substituted C2-C10 alkynyl, (un)substituted C3-C10 cycloalkyl, (un)substituted C3-C10 cycloalkenyl, (un)substituted C3-C10 cycloalkynyl, (un)substituted C3-C10 cycloalkoxy, cyano, C1-C10 alkoxy, C2-C10 alkenyloxy, C2-C10 alkynyloxy, benzyloxy, (un)substituted amino, (un)substituted amido, O(CF3), C(O)O(R1), C(O)(R1), -SO2NR1R2, trifluoromethyl, aryl, aralkyl, heteroaryl and heteroaralkyl. R1 and R2 = H and (un)substituted alkyl; Q3 is (un)substituted alkyl; R11-R19 = H, hydroxy, halogen, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted cycloalkenyl, (un)substituted cycloalkynyl, cyano, alkoxy, alkenyloxy, alkynyloxy, benzyloxy, (un)substituted amino, (un)substituted amido, O(CF3), C(O)O(R41), -C(O)(R41), -SO2NR41R42, trifluoromethyl, aryl, aralkyl, heteroaryl and heteroaralkyl; R41 and R42 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted cycloalkenyl, (un)substituted cycloalkynyl, (un)substituted amino, trifluoromethyl, aryl, aralkyl, heteroaryl and heteroaralkyl; or R41 and R42 may be linked via a C2-C8 (un)substituted alkyl or alkenyl bridge where â‰? carbons may be replaced by O, S or NR46. Q5 = -N(R20)C(O)(CR41R42)1-3-, 1-N(R20)C(O)cycloalkyl (ring size = 3-9), N(R20)C(O)-substituted azacycloalkyl; R20 and R46 = H, hydroxy, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, optionally cycloalkenyl, (un)substituted cycloalkynyl, (un)substituted amino, (un)substituted amido, -C(O)O(R41), -C(O)(R41), -SO2NR4R42, trifluoromethyl, aryl, aralkyl, heteroaryl or heteroaralkyl; and Q6 = (un)substituted aromatic ring, (un)substituted nonaromatic heterocycle, and (un)substituted heteroaromatic ring; or R18 or R19 together with Q5Q6 and the atoms to which they are bonded form an (un)substituted nonaromatic carbocyclic group, (un)substituted nonaromatic heterocyclic group, (un)substituted aryl ring or (un)substituted heteroaryl ring. Addnl. details are given in the claims. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Synthetic Route of 66855-92-3

The Article related to ccr8 chemokine receptor antagonist preparation anti inflammatory antiviral agent, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.Synthetic Route of 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On September 3, 2015, Sherer, Brian; Brugger, Nadia published a patent.Reference of 3-(2-Methoxyphenoxy)benzaldehyde The title of the patent was Preparation of heterocyclic compounds as NaV channel inhibitors. And the patent contained the following:

The title compounds I [Z1 = CR2, C(O), C(S), C(NR); Z2 = CR2, O, S, SO, SO2, NR; X = O, S, SO2, SO, C(O), CO2, C(O)NR, NRC(O), NRC(O)NR, NRSO2, NR; or X is absent; A = (un)substituted alkyl, C5-10 aryl, 3-8 membered saturated or partially unsaturated carbocyclic ring, 3-7 membered heterocylic ring, or a 5-6 membered heteroaryl ring; R1 = R, halo, haloalkyl, etc.; R2-R5 = (independently) = H or alkyl; Y = CH2, O, S, SO2, SO, C(O), CO2, C(O)NR, NRC(O), NRC(O)NR, NRSO2, NR; B = (un)substituted C5-10 aryl or 5-6 membered heteroaryl ring; R6 = R, halo, haloalkyl, etc.; R = H, (un)substituted alkyl, C5-10 aryl, 3-8 membered saturated or partially unsaturated carbocyclic ring, 3-7 membered heterocylic ring having 1-4 heteroatoms selected from N, O, or S, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms selected from N, O, or S; or two R groups on the same atom are taken together with the atom to which they are attached to form C3-10 aryl, 3-8 membered saturated or partially unsaturated carbocyclic ring, 3-7 membered heterocylic ring having 1-4 heteroatoms selected from N, O, or S, or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms selected from N, O, or S; m = 0-3; n = 0-3; q = 0-3; r = 1-2], useful as NaV1.6 inhibitors, were prepared and formulated. E.g., a multi-step synthesis of II, starting from pyrrolidine-1,3-dicarboxylic acid 1-tert-Bu ester and pyridin-2-yl-methylamine, was described. Exemplified compounds I were evaluated for their activity as NaV1.6 inhibitors (data given). The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Reference of 3-(2-Methoxyphenoxy)benzaldehyde

The Article related to heterocyclic compound pyrrolidinecarboxamide preparation sodium channel nav inhibitor, Heterocyclic Compounds (One Hetero Atom): Pyrroles and Pyrrolizines and other aspects.Reference of 3-(2-Methoxyphenoxy)benzaldehyde

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On June 26, 2020, Chen, Lijuan; Li, Yong; Yang, Jianhong published a patent.SDS of cas: 66855-92-3 The title of the patent was Carboline derivative/analogue, its preparation method and application in antitumor drug preparation. And the patent contained the following:

The title carboline derivative/analog is compound I with structural formula shown in claim 1 or its pharmaceutically acceptable salt, wherein X1 and X2 are N or CH, Y is CH2 or NR3, Z is NH, CH2 or O, R1 and R3 are H or C1-3 alkyl, and R2 is C1-6 alkyl, C2-6 alkenyl, etc. The carboline derivative/analog has antitumor activity, and can be used to prepare antitumor drug for breast cancer, cervical cancer, etc., and microtubule inhibitor (microtubule protein degradation agent). The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).SDS of cas: 66855-92-3

The Article related to carboline derivative analog preparation antitumor drug, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.SDS of cas: 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On October 12, 2006, Connolly, Stephen; Linnanen, Tero; Skrinjar, Marco published a patent.Recommanded Product: 66855-92-3 The title of the patent was Preparation of novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases. And the patent contained the following:

The title compounds I [R = II, III (wherein R2, R3 = NR8C(O)CO2H, O(alkyl)CO2H, alkyl(CO2H), CO2H; R4, R5 = halo, CF3, alkyl; p, q = 0-2; R8 = H, alkyl); R1 = IV, V; R6, R7 = H, OMe, OEt], useful in treating CCR8 mediated diseases such as asthma, COPD and rhinitis, were prepared E.g., a multi-step synthesis of VI, starting from tert-Bu 3,9-diazaspiro[5.5]undecane-3-carboxylate hydrochloride and 2-phenoxybenzaldehyde, was given. VI showed IC50 of 0.643 μM against human recombinant chemokine CCR8 receptor binding. Pharmaceutical compositions containing compounds I and their use in therapy are disclosed. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Recommanded Product: 66855-92-3

The Article related to diazaspiroalkane diazaspiroundecane preparation chemokine ccr8 mediated disease treatment, antiasthmatic diazaspiroalkane diazaspiroundecane preparation, chronic obstructive pulmonary disease diazaspiroalkane diazaspiroundecane preparation, rhinitis diazaspiroalkane diazaspiroundecane preparation and other aspects.Recommanded Product: 66855-92-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On October 12, 2006, Connolly, Stephen; Skrinjar, Marco published a patent.Quality Control of 3-(2-Methoxyphenoxy)benzaldehyde The title of the patent was Preparation of novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases. And the patent contained the following:

The title compounds I [R = (un)substituted pyridin-2-one or N-alkyl pyridin-2-one; R1 = II, III; R3, R4 = OMe, OEt], useful in treating CCR8 mediated diseases such as asthma, COPD and rhinitis, were prepared E.g., a multi-step synthesis of IV, starting from tert-Bu 3,9-diazaspiro[5.5]undecane-3-carboxylate hydrochloride and 2-(2-methoxyphenoxy)benzaldehyde, was given. IV showed IC50 of 0.044 μM against human recombinant chemokine CCR8 receptor binding. Pharmaceutical compositions containing compounds I and their use in therapy are disclosed. The experimental process involved the reaction of 3-(2-Methoxyphenoxy)benzaldehyde(cas: 66855-92-3).Quality Control of 3-(2-Methoxyphenoxy)benzaldehyde

The Article related to diazaspiroalkane diazaspiroundecane preparation chemokine ccr8 mediated disease treatment, antiasthmatic diazaspiroalkane diazaspiroundecane preparation, chronic obstructive pulmonary disease diazaspiroalkane diazaspiroundecane preparation, rhinitis diazaspiroalkane diazaspiroundecane preparation and other aspects.Quality Control of 3-(2-Methoxyphenoxy)benzaldehyde

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem